Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 5, 2014, Pages 613-626

  Roubille, Camille ^a   Haraoui, Boulos ^b,c  

^a NOTRE DAME HOSPITAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Institut de Rhumatologie de Montreal   (Canada)

Author keywords

Interstitial lung disease; Leflunomide; Methotrexate; Pneumonitis; Pulmonary fibrosis; Rheumatoid arthritis; Rituximab; TNF inhibitors; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; COLESTYRAMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ACUTE LUNG INJURY; ACUTE RESPIRATORY FAILURE; ALLERGIC PNEUMONITIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; COUGHING; DISEASE EXACERBATION; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FEVER; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LOADING DRUG DOSE; LUNG FIBROSIS; LUNG NODULE; LYMPHOMA; NONCARDIOGENIC LUNG EDEMA; ORGANIZING PNEUMONIA; PLEURA EFFUSION; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 84898813235     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.09.005     Document Type: Article

References (139)

1. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 2013, 25:360-366.
2. Curtis J.R., Patkar N., Xie A., Martin C., Allison J.J., Saag M., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56:1125-1133.
3. Dreyer L., Mellemkjaer L., Andersen A.R., Bennett P., Poulsen U.E., Juulsgaard Ellingsen T., et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013, 72:79-82.
4. Agarwal R., Sharma S.K., Malaviya A.N. Gold-induced hypersensitivity pneumonitis in a patient with rheumatoid arthritis. Clin Exp Rheumatol 1989, 7:89-90.
5. Lateef O., Shakoor N., Balk R.A. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005, 4:723-730.
6. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Br Med J 2009, 339(b2535). The PRISMA Group. 10.1136/bmj.b2535.
7. Cannon G.W., Ward J.R., Clegg D.O., Samuelson C.O., Abbott T.M. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983, 26:1269-1274.
8. Engelbrecht J.A., Calhoon S.L., Scherrer J.J. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum 1983, 26:1275-1278.
9. St Clair E.W., Rice J.R., Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 1985, 145:2035-2038.
10. Louie S., Lillington G.A. Low dose methotrexate pneumonitis in rheumatoid arthritis. Thorax 1986, 41:703-704.
11. Carson C.W., Cannon G.W., Egger M.J., Ward J.R., Clegg D.O. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987, 16:186-195.
12. Searles G., McKendry R.J. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987, 14:1164-1171.
13. Newman E.D., Harrington T.M. Fatal methotrexate pneumonitis in rheumatoid arthritis. Arthritis Rheum 1988, 31:1585-1586.
14. Ridley M.G., Wolfe C.S., Mathews J.A. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988, 47:784-788.
15. McKendry R.J., Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients. Arch Intern Med 1989, 149:685-689.
16. Cook N.J., Carroll G.J. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis 1992, 51:272-274.
17. Hargreaves M.R., Mowat A.G., Benson M.K. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992, 47:628-633.
18. Mulherin D., Cummiskey J.M., Doyle G.D., FitzGerald O. Methotrexate pneumonitis in rheumatoid arthritis-a dramatic response to treatment. Br J Rheumatol 1992, 31:356-357.
19. Bolla G., Disdier P., Harle J.R., Verrot D., Weiller P.J. Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis. Clin Rheumatol 1993, 12:535-537.
20. Hassan W., Carpenter M., Kelly C. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis. Thorax 1993, 48:191.
21. Leduc D., De Vuyst P., Lheureux P., Gevenois P.A., Jacobovitz D., Yernault J.C. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993, 104:1620-1623.
22. Barrera P., Van Ede A., Laan R.F., Van Riel P.L., Boerbooms A.M., Van De Putte L.B. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of five cases in a period of three months. Ann Rheum Dis 1994, 53:479-480.
23. Hilliquin P., Renoux M., Perrot S., Puechal X., Menkes C.J. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996, 35:441-445.
24. Kremer J.M., Alarcon G.S., Weinblatt M.E., Kaymakcian M.V., Macaluso M., Cannon G.W., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997, 40:1829-1837.
25. Ohosone Y., Okano Y., Kameda H., Fujii T., Hama N., Hirakata M., et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997, 24:2299-2303.
26. Salaffi F., Manganelli P., Carotti M., Subiaco S., Lamanna G., Cervini C. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 1997, 16:296-304.
27. Suwa A., Hirakata M., Satoh S., Mimori T., Utsumi K., Inada S. Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy. Clin Exp Rheumatol 1999, 17:355-358.
28. Imokawa S., Colby T.V., Leslie K.O., Helmers R.A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000, 15:373-381.
29. Matsushima H., Takayanagi N., Kawata I., Sakamoto T., Motegi M., Ubukata M., et al. Two fatal cases of methotrexate-induced interstitial pneumonitis. Nihon Kokyuki Gakkai Zasshi 2002, 40:249-255.
30. Hsu P.C., Lan J.L., Hsieh T.Y., Jan Y.J., Huang W.N. Methotrexate pneumonitis in a patient with rheumatoid arthritis. J Microbiol Immunol Infect 2003, 36:137-140.
31. Cho I., Mori S., Imamura F., Kiyofuji C., Sugimoto M. Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis. Mod Rheumatol 2007, 17:256-261.
32. Collins K., Aspey H., Todd A., Saravanan V., Rynne M., Kelly C. Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. Rheumatology (Oxford) 2008, 47:109-110.
33. Bedrossian C.W., Miller W.C., Luna M.A. Methotrexate-induced diffuse interstitial pulmonary fibrosis. South Med J 1979, 72:313-318.
34. van der Veen M.J., Dekker J.J., Dinant H.J., van Soesbergen R.M., Bijlsma J.W. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995, 22:1766-1768.
35. Beyeler C., Jordi B., Gerber N.J., Im Hof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1996, 35:446-452.
36. Cottin V., Tebib J., Massonnet B., Souquet P.J., Bernard J.P. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996, 109:933-938.
37. Dawson J.K., Graham D.R., Desmond J., Fewins H.E., Lynch M.P. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002, 41:262-267.
38. Khadadah M.E., Jayakrishnan B., Al-Gorair S., Al-Mutairi M., Al-Maradni N., Onadeko B., et al. Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis-a prospective study. Rheumatol Int 2002, 22:204-207.
39. Kamata Y., Nara H., Kamimura T., Haneda K., Iwamoto M., Masuyama J., et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004, 43:1201-1204.
40. Collier G., Flood-Page P. A case of acute pneumonitis associated with leflunomide treatment. Respiry Med Extra 2005, 1:35-37.
41. Takeishi M., Akiyama Y., Akiba H., Adachi D., Hirano M., Mimura T. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005, 32:1160-1163.
42. Vallbracht I.I., Popper H.H., Rieber J., Nowak F., Gallenberger S., Piper B., et al. Lethal pneumonitis under leflunomide therapy. Rheumatology (Oxford) 2005, 44:1580-1581.
43. Hirabayashi Y., Shimizu H., Kobayashi N., Kudo K. Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. Intern Med 2006, 45:689-691.
44. Ochi S., Harigai M., Mizoguchi F., Iwai H., Hagiyama H., Oka T., et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol 2006, 16:316-320.
45. Savage R.L., Highton J., Boyd I.W., Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006, 36:162-169.
46. Ju J.H., Kim S.I., Lee J.H., Lee S.I., Yoo W.H., Choe J.Y., et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:2094-2096.
47. Martin N., Innes J.A., Lambert C.M., Turnbull C.M., Wallace W.A. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 2007, 34:1934-1937.
48. Otsuka T., Koyama T., Ohtani R., Niiro H., Yoshizawa S., Harada M., et al. Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. Mod Rheumatol 2008, 18:96-99.
49. Nesheiwat J.P., Dillon K., McGlothan K., Zaman M., Carbone L.D. An elderly man with rheumatoid arthritis and dyspnea. Chest 2009, 135:1090-1093.
50. Wong S.P., Chu C.M., Kan C.H., Tsui H.S., Ng W.L. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol 2009, 15:389-392.
51. Sinha A., Silverstone E.J., O'Sullivan M.M. Gold-induced pneumonitis: computed tomography findings in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001, 40:712-714.
52. Soler M.J., Barroso E., Aranda F.I., Alonso S., Romero S. Fatal gold-induced pneumonitis. Rheumatol Int 2003, 23:207-210.
53. Ishida T., Kotani T., Takeuchi T., Makino S. Pulmonary toxicity after initiation of azathioprine for treatment of interstitial pneumonia in a patient with rheumatoid arthritis. J Rheumatol 2012, 39:1104-1105.
54. Boyd O., Gibbs A.R., Smith A.P. Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis. Br J Rheumatol 1990, 29:222-224.
55. Hamadeh M.A., Atkinson J., Smith L.J. Sulfasalazine-induced pulmonary disease. Chest 1992, 101:1033-1037.
56. Ogawa H., Fujimura M., Nakashima A., Tofuku Y., Ojima T., Kitagawa M. Acute organizing interstitial pneumonia and interstitial nephritis due to salazosulfapyridine in a patient with rheumatoid arthritis. Allergol Int 2003, 52:37-41.
57. Ulubas B., Sahin G., Ozer C., Aydin O., Ozgur E., Apaydin D. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004, 23:249-251.
58. Kramer N., Chuzhin Y., Kaufman L.D., Ritter J.M., Rosenstein E.D. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002, 47:670-671.
59. Courtney P.A., Alderdice J., Whitehead E.M. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2003, 49:617. [author reply 617-618].
60. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004, 33:276-277.
61. Ostor A.J., Crisp A.J., Somerville M.F., Scott D.G. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. Br Med J 2004, 329:1266.
62. Hennum J., Nace J., Shammash E., Gertner E. Infliximab-associated pneumonitis in rheumatoid arthritis. J Rheumatol 2006, 33:1917-1918.
63. Huggett M.T., Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006, 45:1312-1313.
64. Lindsay K., Melsom R., Jacob B.K., Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 2006, 45:1048-1049.
65. Mori S., Imamura F., Kiyofuji C., Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 2006, 16:251-255.
66. Ostor A.J., Chilvers E.R., Somerville M.F., Lim A.Y., Lane S.E., Crisp A.J., et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006, 33:622-628.
67. Quintos-Macasa A.M., Quinet R. Enbrel-induced interstitial lung disease. South Med J 2006, 99:783-784.
68. Schoe A., van der Laan-Baalbergen N.E., Huizinga T.W., Breedveld F.C., van Laar J.M. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 2006, 55:157-159.
69. Villeneuve E., St-Pierre A., Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006, 33:1189-1193.
70. Hagiwara K., Sato T., Takagi-Kobayashi S., Hasegawa S., Shigihara N., Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007, 34:1151-1154.
71. Tournadre A., Ledoux-Eberst J., Poujol D., Dubost J.J., Ristori J.M., Soubrier M. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine 2008, 75:215-218.
72. Taki H., Kawagishi Y., Shinoda K., Hounoki H., Ogawa R., Sugiyama E., et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int 2009, 30:275-276.
73. Dascalu C., Mrejen-Shakin K., Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol 2010, 16:172-174.
74. Sakaida H., Komase Y., Takemura T. Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept. Mod Rheumatol 2010, 20:611-616.
75. Yamazaki H., Isogai S., Sakurai T., Nagasaka K. A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol 2010, 20:518-521.
76. Komiya K., Ishii H., Fujita N., Oka H., Iwata A., Sonoda H., et al. Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. Intern Med 2011, 50:749-751.
77. Cho S.K., Oh I.H., Park C.K., Bae S.C., Sung Y.K. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol Int 2012, 32:1055-1057.
78. Horai Y., Miyamura T., Shimada K., Takahama S., Minami R., Yamamoto M., et al. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther 2012, 37:117-121.
79. Millar A., McKew J., Taggart A. Fatal fibrosing alveolitis with certolizumab. Rheumatology (Oxford) 2012, 51:953-955.
80. Pearce F., Johnson S.R., Courtney P. Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford) 2012, 51:578-580.
81. Glaspole I.N., Hoy R.F., Ryan P.F. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2013, 10.1093/rheumatology/ket1175.
82. Vassallo R., Matteson E., Thomas C.F. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122:1093-1096.
83. Bargagli E., Galeazzi M., Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J. 2004, 24:708.
84. Antoniou K.M., Mamoulaki M., Malagari K., Kritikos H.D., Bouros D., Siafakas N.M., et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007, 25:23-28.
85. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
86. Soubrier M., Jeannin G., Kemeny J.L., Tournadre A., Caillot N., Caillaud D., et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008, 75:362-365.
87. Hadjinicolaou A.V., Nisar M.K., Parfrey H., Chilvers E.R., Ostor A.J. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012, 51:653-662.
88. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761-1769.
89. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
90. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009, 19:12-19.
91. Ikegawa K., Hanaoka M., Ushiki A., Yamamoto H., Kubo K. A case of organizing pneumonia induced by tocilizumab. Intern Med 2011, 50:2191-2193.
92. Kawashiri S.Y., Kawakami A., Sakamoto N., Ishimatsu Y., Eguchi K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2012, 32:4023-4026.
93. Wada T., Akiyama Y., Yokota K., Sato K., Funakubo Y., Mimura T. A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept. Nihon Rinsho Meneki Gakkai Kaishi 2012, 35:433-438.
94. Acute lymphocytic leukemia in children: maintenance therapy with methotrexate administered intermittently. Acute Leukemia Group B. J Am Med Assoc 1969, 207:923-928.
95. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104.
96. Kinder A.J., Hassell A.B., Brand J., Brownfield A., Grove M., Shadforth M.F. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 2005, 44:61-66.
97. Conway R., Low C., Coughlan R.J., O'Donnell M., Carey J.J. Methotrexate and interstitial lung disease in rheumatoid arthritis-a systematic literature review and meta-analysis. Arthritis Rheum 2012, 64:S918. [abstract].
98. Cannon G.W. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am 1997, 23:917-937.
99. Padley S.P., Adler B., Hansell D.M., Muller N.L. High-resolution computed tomography of drug-induced lung disease. Clin Radiol 1992, 46:232-236.
100. Arakawa H., Yamasaki M., Kurihara Y., Yamada H., Nakajima Y. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging 2003, 18:231-236.
101. Schnabel A., Richter C., Bauerfeind S., Gross W.L. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997, 52:377-379.
102. Camus P., Fanton A., Bonniaud P., Camus C., Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004, 71:301-326.
103. Alarcon G.S., Kremer J.M., Macaluso M., Weinblatt M.E., Cannon G.W., Palmer W.R., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997, 127:356-364.
104. Golden M.R., Katz R.S., Balk R.A., Golden H.E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995, 22:1043-1047.
105. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004, 363:461.
106. Sakai F., Noma S., Kurihara Y., Yamada H., Azuma A., Kudoh S., et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005, 15:173-179.
107. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006, 54:1435-1439.
108. *31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker?. Ann Rheum Dis 2013, 72:153-155. Rheumatoid Arthritis-Interstitial Lung Disease Study Consortium, Tsuchiya N, Tohma S.
109. Sawada T., Inokuma S., Sato T., Otsuka T., Saeki Y., Takeuchi T., et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1069-1072.
110. Sato T., Inokuma S., Sagawa A., Matsuda T., Takemura T., Otsuka T., et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1265-1268.
111. Chikura B., Lane S., Dawson J.K. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009, 48:1065-1068.
112. Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:189-194.
113. Koike T., Harigai M., Inokuma S., Inoue K., Ishiguro N., Ryu J., et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009, 36:898-906.
114. Wolfe F., Caplan L., Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007, 36:172-178.
115. Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., Pego-Reigosa J.M., Retamozo S., Bove A., et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011, 41:256-264.
116. Panopoulos S.T., Sfikakis P.P. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011, 17:362-367.
117. Koike T., Harigai M., Inokuma S., Ishiguro N., Ryu J., Takeuchi T., et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011, 21:343-351.
118. Nakashita T., Motojima S., Fujio N., Jibatake A. The incidence of exacerbation of pre-existing interstitial lung disease (ILD) is higher in TNF blockers than in non-TNF blockers in RA. Arthritis Rheum 2012, 64(Suppl. 10):S573-S574.
119. Khasnis A.A., Calabrese L.H. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum 2010, 40:147-163.
120. Koike T., Harigai M., Ishiguro N., Inokuma S., Takei S., Takeuchi T., et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012, 22:498-508.
121. Sen S., Peltz C., Jordan K., Boes T.J. Infliximab-induced nonspecific interstitial pneumonia. Am J Med Sci 2012, 344:75-78.
122. Wiener C.M., Muse V.V., Mark E.J. Case records of the Massachusetts General Hospital. Case 33-2008. A 63-year-old woman with dyspnea on exertion. N Engl J Med 2008, 359:1823-1832.
123. Allanore Y., Devos-Francois G., Caramella C., Boumier P., Jounieaux V., Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006, 65:834-835.
124. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Symmons D.P., et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010, 69:1086-1091. BCC Consortium.
125. Herrinton L.J., Harrold L.R., Liu L., Raebel M.A., Taharka A., Winthrop K.L., et al. Association between anti-TNF-alpha therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 2013, 22:394-402.
126. Kuroki M., Noguchi Y., Shimono M., Tomono K., Tashiro T., Obata Y., et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 2003, 170:567-574.
127. Elias J.A. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms. Am Rev Respir Dis 1988, 138:652-658.
128. Sullivan D.E., Ferris M., Nguyen H., Abboud E., Brody A.R. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med 2009, 13:1866-1876.
129. Miyazaki Y., Araki K., Vesin C., Garcia I., Kapanci Y., Whitsett J.A., et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995, 96:250-259.
130. Liote H., Liote F., Seroussi B., Mayaud C., Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010, 35:681-687.
131. Atkins S.R., Turesson C., Myers J.L., Tazelaar H.D., Ryu J.H., Matteson E.L., et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006, 54:635-641.
132. Dass S., Atzeni F., Vital E., Bingham S., Buch M., Beirne P., et al. Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Ann Rheum Dis 2011, 70(Suppl. 3):71.
133. Becerra G., Cambridge M. Safety and efficacy of rituximab in patients with rheumatoid arthritis and lung involvement. Ann Rheum Dis 2013, 72(Suppl. 3):450.
134. Matteson E.L., Dellaripa P.F., Ryu J.H., Crowson C.S., Hartman T.E., Bongartz T. Open-label pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Arthritis Rheum 2011, 63(Suppl. 10):2212.
135. Nannini C., Ryu J.H., Matteson E.L. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:340-346.
136. Bongartz T., Nannini C., Medina-Velasquez Y.F., Achenbach S.J., Crowson C.S., Ryu J.H., et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010, 62:1583-1591.
137. Muller N.L., White D.A., Jiang H., Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004, 91(Suppl. 2):S24-S30.
138. Saravanan V., Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:787-789.
139. Askling J., Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:138-144.